Radioimmunotherapy for breast cancer: Treatment of a patient with I-131 L6 chimeric monoclonal antibody

S. J. DeNardo, K. A. Warhoe, L. F. O'Grady, I. Hellstrom, K. E. Hellstrom, S. L. Mills, D. J. Macey, J. E. Goodnight, G. L. DeNardo

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


We report the first treatment of metastatic breast cancer by systemic radioimmunotherapy. The serial therapy doses were chosen based on quantitative imaging data in a treatment planning approach. A terminally ill patient with aggressive, locally advanced breast cancer who had failed radiation treatment and chemotherapy was injected intravenously with radiolabeled I-131 chimeric L6, a human-mouse chimeric IgG1 monoclonal antibody to adenocarcinoma. Initially, an imaging 10 mCi dose of I-131 chimeric L6 (dose 1) deposited 8.8% of the injected dose in her chest wall tumor at 48 hours. Ten days later the patient was given a 150 mCi I-131 chimeric L6 dose (dose 2) followed three weeks later by a 100 mCi dose (dose 3). Tumor uptake and retention were comparable for doses 1 and 2, and decreased for dose 3. Following dose 3 the patient developed a manageable thrombocytopenia and transient Grade IV granulocytopenia. The tumor was observed to decrease in size with peak tumor regression occurring two weeks after dose 3. This partial response (PR) was achieved by radioimmunotherapy at a time when conventional therapy had been unable to impact the growth of the patient's massive and aggressive tumor.

Original languageEnglish (US)
Pages (from-to)221-230
Number of pages10
JournalInternational Journal of Biological Markers
Issue number4
StatePublished - 1991

ASJC Scopus subject areas

  • Biochemistry
  • Immunology


Dive into the research topics of 'Radioimmunotherapy for breast cancer: Treatment of a patient with I-131 L6 chimeric monoclonal antibody'. Together they form a unique fingerprint.

Cite this